Eisai and Biogen's Subcutaneous LEQEMBI Granted China NMPA Priority Review

The National Medical Products Administration (NMPA) in China has granted priority review to the subcutaneous formulation of LEQEMBI (iqbifigimod), developed by Eisai and co-developed by Biogen, for the treatment of early-stage Alzheimer's disease. The decision, effective February 09, 2026, reflects expedited regulatory consideration for the therapy, potentially accelerating its approval timeline in mainland China. Key figures: The subcutaneous formulation is designed for once-weekly dosing, with a target approval date expected in the first quarter of 2026. The priority review underscores the NMPA's focus on therapies addressing neurodegenerative diseases, following a positive review by the European Medicines Agency in May 2025.